The PALATINE trial (NCT03870919) aims to investigate the integration of locoregional treatment with palbociclib in patients with de novo, treatment-naïve, stage IV ER-positive, and HER2-negative breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.